Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment

Abstract

IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095-1105.].